According to a new report, published by KBV research, The Global Helicobacter Pylori Diagnostics Market size is expected to reach $805.9 Million by 2030, rising at a market growth of 5.5% CAGR during the forecast period.
The Invasive segment is showcasing a CAGR of 6.4% during (2023 - 2030). The segment's growth is because rapid urease test (RUT), microbiological culture, and biopsy-based polymerase chain reaction are invasive procedures. It is commonly known that non-invasive methods include serological examinations, urea breath tests, and stool antigen testing (SAT). The RUT is another invasive test used as a standard procedure in clinical practice. Culture is another invading tactic. Also, microbiological cultures obtained from endoscopy-based stomach biopsies are indisputable evidence for H. pylori analysis.
The Diagnostics Laboratories segment is leading the Global Helicobacter Pylori Diagnostics Market by End User in 2022 thereby, achieving a market value of $437.2 Million by 2030. This is due to the presence of cutting-edge lab facilities, the knowledge of lab specialists, regulatory compliance, a variety of testing services, and ease of accessibility. Additionally, diagnostic laboratories provide various testing services, including invasive and non-invasive procedures, enabling healthcare practitioners to select the most suitable test for each patient which is aiding the segment’s expansion.
The Point of Care Test segment has shown the growth rate of 8.1% during (2023 - 2030). The segment's growth is due to the use of IgG serology, 13C-urea breath test (UBT), and monoclonal stool antigen non-invasive diagnostic tests for Helicobacter pylori that can be used at the point of care (POC) in primary care. Both patients and healthcare professionals find this testing system simple to use. External facilities are not needed for additional assistance. After the patient has ingested the C-14-activated capsule, the test results will be accessible in 1 to 20 minutes. The rapid results and their use in primary care are expected to drive the segment's growth.
The North America market dominated the Global Helicobacter Pylori Diagnostics Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $300.2 Million by 2030. The Europe market is exhibiting a CAGR of 5.3% during (2023 - 2030). Additionally, The Asia Pacific market would register a CAGR of 6.3% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/helicobacter-pylori-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Cardinal Health, Inc., Biohit Oyj, Abbott Laboratories, Quidel Corporation, Gulf Coast Scientific, Inc. (Gulf Coast Medical Center), Meridian Bioscience, Inc. (SD Biosensor Co., Ltd.), Avanos Medical, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc. and F. Hoffmann-La Roche Ltd.
By Test Type
By End User
By Method
By Geography
Companies Profiled
Unique Offerings 
